Ombion Centre for Animal-free Biomedical Translation celebrates launch and site opening

On July 7, 2025, the Ombion Centre for Animal-free Biomedical Translation was officially launched and opened its location at Utrecht Science Park. The centre promotes the transition to animal-free medical innovations and collaborates with over 60 partners on research, education, and practical implementation.
On 7 July 2025, the Centre for Animal-free Biomedical Translation, supported by the Dutch National Growth Fund, was officially launched under its new name: Ombion Centre for Animal-free Biomedical Translation.
The launch of Ombion took place during a festive event in presence of many guests at the Life Sciences Incubator building at Utrecht Science Park. It also marked the opening of Ombion’s on-site centre at the same location. The opening of the centre and the unveiling of the new name and logo was performed by Marten van den Berg, Director General Agriculture of the Ministry of Agriculture, Fisheries, Food Security and Nature, together with Daniela Salvatori, Ombion’s Scientific Director ad interim.
The Ministry of Agriculture, Fisheries, Food Security and Nature originally submitted the CPBT National Growth Fund proposal, which was granted last year. This has now resulted in the establishment of the centre. In his speech, Director General van den Berg underlined the ministry’s support for the Ombion Growth Fund initiative and its goals.
The afternoon program also included pitch-style presentations of Ombion’s main projects and activities, highlighting the various organisations collaborating within the public-private partnership and the involved disease models.
After the presentations, an information market featuring research materials and demonstrations of the projects that are part of the Ombion programme inspired attendees, followed by a lively networking session that concluded the event.
Start of operational phase
The launch is an important milestone for Ombion as it is also the starting point of its operational phase. Initially, the main focus of the centre will be on four transition projects, demonstrating the benefits of animal-free translation techniques in specific medical research fields: ALS, Cystic Fibrosis, Osteoarthritis & Rheumatoid Arthritis, and Asthma & COPD. The new centre will also offer education, training, advice, and support to enhance the acceptance and use of animal-free biomedical innovations. With all activities combined, Ombion will run an integrated programme that accelerates the transition to animal-free translation and strengthens the earning capacity of the Netherlands.
Daniela Salvatori commented: “Today marks a pivotal moment as we officially open the centre and launch our partnership, united by a shared mission to accelerate the transition to animal-free biomedical translation. The energy in the room was truly inspiring – a reflection of the passion and commitment driving this initiative forward. I am looking forward to see the community grow, and I hope that our private and public partnership will consolidate and be open to new projects and initiatives, both nationally and internationally.”
Partnership
Within Ombion, over 60 partners representing academia, research organisations, industry, regulatory organisations, government bodies, patient organisations, NGOs, and others are working together to pave the way for the transition to animal-free biomedical translation. Founding partners of Ombion are Utrecht University, HU University of Applied Sciences Utrecht, UMC Utrecht, UMCG, and Maastricht University.
About Ombion Centre for Animal-free Biomedical Translation
Ombion Centre for Animal-free Biomedical Translation is a national centre for valorising and disseminating animal-free innovations and expertise. It aims to improve and accelerate the transition of new biomedical innovations to patients and users, at lower costs, and without the use of animals. This will lead to safer, more effective, and better medicines while reducing animal testing. Together with a large number of national and international partners, Ombion will work on the development and dissemination of animal-free biomedical innovations and expertise.

Utrecht Science Week: Boudewijn Visscher on the Future of Washable Incontinence Materials
In the Netherlands, approximately 85 million kilograms of waste from incontinence materials are generated every year. Washable alternatives could help reduce this waste stream, but switching to washable materials is not yet common practice in healthcare. What is holding back this transition, and what is needed to make washable incontinence materials more widely applicable?

Utrecht Science Week: René van Westen on a colder Netherlands in a warmer world
The Earth is warming, yet the Netherlands could face much colder winters in the future. It may sound contradictory, but the explanation lies in the Atlantic Meridional Overturning Circulation (AMOC), a large system of ocean currents that transports heat and salt through the Atlantic Ocean. This circulation plays an important role in the mild climate that we are accustomed to in the Netherlands.

Utrecht Science week: The Future of Veterinary Medicine Requires New Ways of Working Together
Veterinary medicine is changing rapidly. New technologies and AI are entering the field, issues surrounding animal health and welfare are becoming increasingly complex, and the labour market is under pressure. At the same time, there is a growing need for professionals who not only have up-to-date expertise, but who can continue to develop throughout their careers and collaborate across disciplines.

Opening Utrecht Science Week with keynote by Juliette Legler on the hidden influence of environmental chemicals
On Friday, September 25, the annual science festival ‘Utrecht Science Week’ kicks off once again at Utrecht Science Park. We are pleased to announce that this year, Prof. Dr. Ir. Juliette Legler will deliver the Utrecht Science Lecture. Juliette Legler is Professor of Toxicology at the Faculty of Veterinary Medicine at Utrecht University and leads the ‘One Health Toxicology’ group at the Institute for Risk Assessment Sciences (IRAS).